A detailed history of Bain Capital Life Sciences Investors, LLC transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Bain Capital Life Sciences Investors, LLC holds 2,485,638 shares of AVIR stock, worth $8.38 Million. This represents 1.49% of its overall portfolio holdings.

Number of Shares
2,485,638
Previous 2,485,638 -0.0%
Holding current value
$8.38 Million
Previous $8.23 Million 1.2%
% of portfolio
1.49%
Previous 1.68%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022

SELL
$7.67 - $44.59 $9.31 Million - $54.1 Million
-1,214,362 Reduced 32.82%
2,485,638 $22.2 Million
Q3 2021

Nov 15, 2021

SELL
$21.33 - $35.06 $40.9 Million - $67.2 Million
-1,915,659 Reduced 34.11%
3,700,000 $130 Million
Q4 2020

Feb 16, 2021

BUY
$26.36 - $41.78 $148 Million - $235 Million
5,615,659 New
5,615,659 $235 Million

Others Institutions Holding AVIR

About Atea Pharmaceuticals, Inc.


  • Ticker AVIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,258,600
  • Market Cap $281M
  • Description
  • Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...
More about AVIR
Track This Portfolio

Track Bain Capital Life Sciences Investors, LLC Portfolio

Follow Bain Capital Life Sciences Investors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bain Capital Life Sciences Investors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bain Capital Life Sciences Investors, LLC with notifications on news.